{"ticker": {"uuid": "6d06dad0-ad75-456c-87a2-a7c8dee321de", "symbol": "IVVD", "name": "Invivyd Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Not Too Worried About Invivyd's (NASDAQ:IVVD) Cash Burn Situation", "summary": "Invivyd (NASDAQ:IVVD) has a cash runway of about 2.3 years and analysts predict the company will reach cashflow breakeven in 3 years. While its cash burn of US$79m represents 32% of its market capitalization, which could lead to dilution if more capital is needed, its 52% revenue", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ivvd/invivyd/news/heres-why-were-not-too-worried-about-invivyds-nasdaqivvd-cas", "source_name": "Simply Wall Street", "published_at": "2026-07-10T18:11:22", "published_display": "10 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK)", "summary": "Analysts have provided varied ratings for three healthcare companies. Stifel Nicolaus maintained a Buy rating for Cipher Pharmaceuticals with a C$22.00 price target, while Cantor Fitzgerald maintained a Buy rating for Invivyd with a $10.00 price target. Morgan Stanley, however, i", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/3223856/analysts-conflicted-on-these-healthcare-names-cipher-pharmaceuticals-othercphrf-invivyd-ivvd-and-merck-company-mrk/", "source_name": "The Globe and Mail", "published_at": "2026-07-10T13:10:02", "published_display": "10 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Inc updates investors on its antiviral pipeline as Nasdaq-listed biotech advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQenBFbDV6Ymt1S1BCTWN0Wk5CanRrOHdXQVFKTFdFeWdYai0tN3NGSmltWkcyS2JXUGtjVTFXNzBoOVlXd2FxYmtiRU5DQ0Y1UzdwZ1piQ2VHY1NnOVpTcENvQ2ZiNThVR3NmcHI4SzNERjN2SVBuQ3R1Y2E2UV93bVJ1OE80UlZCWE5RaUlPRldmeHdTZXVpSHE3TVFHc3Jiel9HeEJhREZYdnAzQlhfZ3J0bm04Y29ielRzaGlxUFpsaUJ2R0lhNnp2aw?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-08T19:48:57+00:00", "published_display": "08 Jul 2026 19:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Invivyd stock rating on regulatory path", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Invivyd Inc. (NASDAQ:IVVD) following recent regulatory developments regarding its COVID-19 antibody treatment, PEMGARDA. The FDA issued a Notice of Termination for PEMGARDA's Emergency Use Authorization, ef", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-invivyd-stock-rating-on-regulatory-path-93CH-4781353", "source_name": "Investing.com", "published_at": "2026-07-08T17:09:06", "published_display": "08 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Invivyd stock rating on regulatory path By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Invivyd Inc. (NASDAQ:IVVD) following recent regulatory developments regarding its COVID-19 antibody treatment, PEMGARDA. The FDA issued a Notice of Termination for PEMGARDA's Emergency Use Authorization, ef", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-reiterates-invivyd-stock-rating-on-regulatory-path-93CH-2590809", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T11:40:48", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-Down", "summary": "Invivyd, Inc. announced that the FDA issued a notice of termination for the Emergency Use Authorization (EUA) of PEMGARDA (pemivibart) due to the wind-down of the COVID-19 Public Health Emergency Declaration by the U.S. Department of Health and Human Services. The termination bec", "url": "https://www.moomoo.com/news/post/72540865/invivyd-inc-announces-fda-notice-of-termination-for-pemgarda-eua", "source_name": "Moomoo", "published_at": "2026-07-08T06:43:41", "published_display": "08 Jul 2026 06:43", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Inc stock and Covid antibody focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTzAxb01JbGh3UzZXZHl6N2lGWUdSOXpGVTdZOTdWbGYzUzRDTkJQeDlJUXprbzdIVXNGVEpYYUlIRE8xb015UVBISUhteHdOakRWZ09ja3RBeEdfazBLdnFMRzltUlE0X1VJekFqSFpiaDFQNDYzbXgzWWdkR1hwVlhySnh5c1psMUhzOWJDRkd4Yk1vWkt1S0pBc3VORktlMW1Z?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-07T14:22:39+00:00", "published_display": "07 Jul 2026 14:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 \u2014 Invivyd Eyes Full FDA Approval", "summary": "", "url": "https://finance.yahoo.com/m/deafdf7c-ee7e-3b54-bb3d-bb9ab2b2d2f7/ivvd-stock-drops-as-pemgarda.html", "source_name": "Stocktwits", "published_at": "2026-07-06T17:39:27+00:00", "published_display": "06 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd receives 12-month notice of EUA termination for PEMGARDA, plans FDA dialogue", "summary": "Invivyd has received a 12-month notice from the FDA regarding the termination of the Emergency Use Authorization (EUA) for its drug PEMGARDA, effective June 29, 2027, following a similar declaration from HHS concerning COVID-19 EUAs. The company is actively discussing with the FD", "url": "https://www.tradingview.com/news/tradingview:4c29114ade7cb:0-invivyd-receives-12-month-notice-of-eua-termination-for-pemgarda-plans-fda-dialogue/", "source_name": "TradingView", "published_at": "2026-07-06T16:40:48", "published_display": "06 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVVD Stock Tanks 19% Today \u2013 But This Analyst Believes It Has A Potential Upside Of Over 730%", "summary": "Invivyd Inc. (IVVD) stock dropped over 19% after reporting first-quarter revenue of $13.7 million, significantly missing analyst estimates of $18 million. Despite this, H.C. Wainwright & Co. reiterated a 'Buy' rating and a $10 price target, suggesting a potential upside of over 7", "url": "https://stocktwits.com/news-articles/markets/equity/ivvd-stock-fell-today-but-this-analyst-sees-730-percent-upside/cZX1UFNReSa", "source_name": "Stocktwits", "published_at": "2026-07-06T16:14:45", "published_display": "06 Jul 2026 16:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Gets FDA Notice of Pemgarda COVID-19 Emergency Use Authorization Termination", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/invivyd-gets-fda-notice-pemgarda-114042026.html", "source_name": "MT Newswires", "published_at": "2026-07-06T11:40:42+00:00", "published_display": "06 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd receives FDA termination notice for PEMGARDA EUA", "summary": "Invivyd (NASDAQ:IVVD) announced that the FDA's Emergency Use Authorization for its COVID-19 antibody treatment, PEMGARDA, will terminate on June 29, 2027. This decision aligns with the Department of Health and Human Services' conclusion of the national COVID-19 emergency declarat", "url": "https://grafa.com/en/news/united-states/invivyd-ivvd-pemgarda-eua-termination-notice-2027", "source_name": "grafa.com", "published_at": "2026-07-06T12:21:00", "published_display": "06 Jul 2026 12:21", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Announces Receipt of Twelve Months\u2019 Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA\u00ae and Provides an Update on Next Steps with the U.S. FDA", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/invivyd-announces-receipt-twelve-months-110100684.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T11:01:00+00:00", "published_display": "06 Jul 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd (NASDAQ: IVVD) faces 2027 end of PEMGARDA COVID EUA", "summary": "Invivyd (NASDAQ: IVVD) announced that the FDA has issued a Notice of Termination for the Emergency Use Authorization (EUA) of its COVID-19 monoclonal antibody, PEMGARDA, effective June 29, 2027. This follows the HHS's decision to end the COVID-19 EUA declaration. PEMGARDA will re", "url": "https://www.stocktitan.net/sec-filings/IVVD/8-k-invivyd-inc-reports-material-event-d43329ab1d20.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:11:44", "published_display": "06 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEMGARDA faces 2027 EUA end as Invivyd talks next steps with FDA", "summary": "Invivyd (Nasdaq: IVVD) has received advanced notice from the FDA that the Emergency Use Authorization (EUA) for its COVID-19 preventative treatment, PEMGARDA, will terminate on June 29, 2027, following the planned end of the HHS COVID-19 EUA declaration. Despite this, Invivyd is ", "url": "https://www.stocktitan.net/news/IVVD/invivyd-announces-receipt-of-twelve-months-advanced-notice-of-jcshku0pngsg.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:11:43", "published_display": "06 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVVD - Invivyd Inc Short Interest", "summary": "This article provides a detailed financial overview and short interest data for Invivyd Inc (IVVD). It includes key metrics such as market capitalization, sales, earnings per share, and various performance indicators. The data highlights the company's short interest, institutiona", "url": "https://finviz.com/stock?t=IVVD&p=w&r=y2&ty=si", "source_name": "Finviz", "published_at": "2026-07-05T19:40:40", "published_display": "05 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Invivyd, Inc. \u2013 NASDAQ:IVVD", "summary": "This article provides the \"Price to sales forward\" metric for Invivyd, Inc. (NASDAQ: IVVD). It appears to be a financial data snippet from TradingView, focusing on a single financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-IVVD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T16:11:44", "published_display": "05 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Invivyd, Inc. \u2013 NASDAQ:IVVD", "summary": "This article provides financial information for Invivyd, Inc. (NASDAQ: IVVD), specifically focusing on its forward price-to-earnings ratio. It directs users to TradingView for market data, technical analysis, and other financial tools related to the company. The content appears t", "url": "https://www.tradingview.com/symbols/NASDAQ-IVVD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:39:42", "published_display": "05 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVVD - Invivyd Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Invivyd Inc. (IVVD), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider/institutional ownership, short interes", "url": "https://finviz.com/stock?t=IVVD&ta=1&p=d&ty=fc", "source_name": "Finviz", "published_at": "2026-07-04T12:09:47", "published_display": "04 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Invivyd, Inc. \u2013 NASDAQ:IVVD", "summary": "This article briefly presents the \"Enterprise value to EBITDA forward\" metric for Invivyd, Inc. (NASDAQ:IVVD) within the TradingView platform. It shows the company's stock market information and indicates that the market is closed with no trades. The article is a stub, likely par", "url": "https://www.tradingview.com/symbols/NASDAQ-IVVD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:10:44", "published_display": "04 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Invivyd, Inc. announced that it granted 14 newly hired non-executive employees options to purchase 493,000 shares of its common stock as an inducement to employment. These options were issued on July 1, 2026, under Nasdaq Listing Rule 5635(c)(4) and the company's 2026 Inducement ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IVVD/pressreleases/3095627/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/", "source_name": "The Globe and Mail", "published_at": "2026-07-03T03:10:44", "published_display": "03 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd gives 14 new hires stock options worth 493,000 shares", "summary": "Invivyd (Nasdaq: IVVD) announced it granted 493,000 stock options to 14 newly hired non-executive employees as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.8544 per share, matching the closing price on t", "url": "https://www.stocktitan.net/news/IVVD/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-oyczlwl9qiln.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:12:30", "published_display": "02 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Value Benchmark Index", "summary": "Invivyd, Inc. (NasdaqGM: IVVD) has been added to the Russell Microcap Value Benchmark Index. This news follows a series of recent index inclusions for the biopharmaceutical company, which also saw its addition to the Russell 2000 Index and Russell 2000 Value Benchmark Index on th", "url": "https://www.marketscreener.com/news/invivyd-inc-nasdaqgm-ivvd-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8bff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:15:24", "published_display": "29 Jun 2026 16:15", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Index", "summary": "Invivyd, Inc. (NasdaqGM: IVVD) has been added to the Russell Microcap Index. This follows a recent period of news for the biopharmaceutical company, including its completion of enrollment in a Phase 3 clinical trial for a COVID-19 antibody. The company specializes in developing a", "url": "https://www.marketscreener.com/news/invivyd-inc-nasdaqgm-ivvd-added-to-russell-microcap-index-ce7f5fdedd88f721", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:09:55", "published_display": "29 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc. Actuals & Estimates (NASDAQ:IVVD)", "summary": "This article provides an overview of Invivyd, Inc. (NASDAQ: IVVD) stock, including its current price, historical performance, analyst forecasts, and key financial metrics. It details earnings, revenue, market capitalization, and volatility, and confirms that the company does not ", "url": "https://www.tradingview.com/symbols/NASDAQ-IVVD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:37", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Shareholder Notice", "summary": "Faruqi & Faruqi, LLP is investigating potential securities claims against Invivyd, Inc. (NASDAQ: IVVD) and encouraging investors who lost over $100,000 to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Invivyd made misleading statements ", "url": "https://www.newsfilecorp.com/release/157908/Invivyd-Shareholder-Notice?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-25T02:10:07", "published_display": "25 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lobbying Update: $60,000 of INVIVYD INC. lobbying was just disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbnRjSXdPYmZiaURVam16VHhkQ0ZuNGNPQUtUalFvc3ZZZkd3MktFY1lCY1R6U1lBbWs4dF9mLTN0WVBEaE9tLXZUOEo4WlhBZnh1QVpqLTVndTFLY0NoN3drMUw5Vm4za01yd0xFR2c3akNPRzJDaWJHV1M2ZXFKVVBPZml0cmlIaURyNTNnYzNXWVlLNHByWjY1aHpKSWpFWXRUcG1hazJOZDA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Inc (IVVD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Invivyd Inc (IVVD) has a robust financial status with a current financial score of 8.37, ranking 63 out of 157 in the Pharmaceuticals industry. The company reported a significant year-over-year revenue increase of 21.59% to 13.74M and a net profit increase of 154.16%. Its strong ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ivvd/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T08:10:05", "published_display": "23 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Biotechnology Select Industry Index", "summary": "Invivyd, Inc. (NasdaqGM: IVVD) has been removed from the S&P Biotechnology Select Industry Index. This news follows several recent updates from the company, including the completion of enrollment in its Phase 3 LIBERTY clinical trial for its VYD2311 antibody against COVID-19. Inv", "url": "https://www.marketscreener.com/news/invivyd-inc-nasdaqgm-ivvd-dropped-from-s-p-biotechnology-select-industry-index-ce7f5cd3d88af222", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:40:21", "published_display": "22 Jun 2026 01:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311", "summary": "Invivyd Inc. (NASDAQ: IVVD) has dosed the first participants in its LIBERTY Phase 3 clinical trial for VYD2311, a monoclonal antibody candidate for COVID-19 prevention. This study will compare VYD2311's safety and tolerability against mRNA COVID-19 vaccines in approximately 210 h", "url": "https://www.insidermonkey.com/blog/invivyd-ivvd-doses-first-participants-in-phase-3-trial-for-vyd2311-1783916/", "source_name": "Insider Monkey", "published_at": "2026-06-19T07:14:42", "published_display": "19 Jun 2026 07:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Invivyd Inc (IVVD) has an earnings forecast score of 8.67, ranking 13th in the Pharmaceuticals industry. Analysts have set an average price target of $10.00 for IVVD, with most recommending a \"Buy\" trend. The company's expected revenue for the next quarter is $14.40 million, and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ivvd/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:03", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 79, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/invivyd-apos-stage-trial-covid-113133374.html", "source_name": "MT Newswires", "published_at": "2026-06-16T11:31:33+00:00", "published_display": "16 Jun 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/invivyd-announces-completion-enrollment-phase-110100561.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:01:00+00:00", "published_display": "16 Jun 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd doses first participants in Phase 3 COVID-19 trial", "summary": "", "url": "https://finance.yahoo.com/m/b248705d-ddec-3f8d-b220-660c9bc473f6/invivyd-doses-first.html", "source_name": "Proactive", "published_at": "2026-06-09T16:22:00+00:00", "published_display": "09 Jun 2026 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Doses First Participants in Phase 3 Trial of COVID-19 Antibody VYD2311", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/invivyd-doses-first-participants-phase-121506548.html", "source_name": "MT Newswires", "published_at": "2026-06-09T12:15:06+00:00", "published_display": "09 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New COVID shot alternative faces off with mRNA vaccine in Invivyd trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWEpNakhUaUdha1lVNktOTnNqaDd5cG5HYld6ZThzaGpFVXBpQmROb0FycGstOFduSDlpeWk1WlRPSmJwei1naXh6N2RhNUllQWt5YzZtVml5ckpEM1JaTUJsRV9KSEtJQUNqOTF1d0pTUFVtMGVkTDZsYTBEUDYtTUtsM0dzamJNYWpWdzFPUHZ6UEpZNkZRNW1GanF0X2RZNVgxWFZ4c1pCNkZfcl9pelI3dklLX1V5a0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd offers stock options to 17 new hires at $1.22 each", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMEEzZm5FV1Y4cExMRm1Xa2VablFZMW9wSGdRS2ZhOWpLbThnNm9HTWprUElYTEtZOUs1N1owTXliSGQzbVRYa3MzODlNc1lta2c0d0t4NVRQbDRFRFBnOXZXN3VPOExQdnh2dVl1WWtYZnBNRnpqVzRkSG13RWs4NVJTME9YTXpYR2o0MWdJemYzVGNBSnY0NUVKRWFEUzVzd2ljUlE3TzFWekp3VmdLWTZ0dzd4b19ZMGhsSnBR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COVID antibody trial fully enrolled as Invivyd targets Q3 2026 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPRnlXX3BYbTl6NHkzNmRSbXVWeHBPbHpXYkU4d2xYaXZOazNHVzI3WkhhOUxnTDRHNDNYVHVwZkh1cFBma3lyUGlRaEtWUUdRQ2lPQWoyb3gxVmR6OENjS1YwZ0pReXQ0UkVRckg4aHRxU0h5N1NxQktUbEpvWm5yXzY3LW1kQmhScjlIWW9pc3lzWkp4T3hQSzRQeksyQ2dtSmF5VnZjQk5jTWJ0LWVEdG4xRU9ERFNRS0pRSA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd lines up three June investor events with live webcasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNM0tISERzN1Q2M0JXRU4xMTA2d3Z0ZWFTc0lkRlQ3YkpNSHQteHRfQ1FXQ1hqYzYwanFidjZleTY2d3Q0LUVybXM3SXU4Y0ItNEVmanQxLWhrN0hmTW1VUUdncmwxWnRXTEZoek5ILTQwNFBfNS1kcUxRQXg5dzR1VVVWVE1lMzNmSERueUNQQTh0cW8xUkpLcmFHZTYtbXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNX0R5UDVoWmFwZEtYZWV1WGJmb0lOY3pxSWF0eUluc0hUbU4zNHNUMzR1TTNBWWZMVnhuV1ZIcWRick5lU0ZMeGIxN2VhbGlPTWt0d1R1RGtac2tEN3h3ZVY2QU0wc0ZFaWFJUDE0ZHJrZVdRTWJBM3ItRUxwUE9hT3c1ZWhKdGRvRGNZRTRGYmZMaHgtSnlJ?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Invivyd Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOVDJOdTFuQzN6T1I2amZJdTNCNV9ZUEFnWDdZWmhOZWxUaTg1YWdMSjRldTNKUXJzQ1ctZFBJYjcyWkRMelcwM3NkbE9hSzZNNExKZ3RjaFZGa09PRnZDN3VkTGR1MTN4Wl9VOENYRzhCNVJFTHVQaDNFbDd4U2Y2dnRfYm5lbzRxS2d6ajdQd2xQSk0teW5pQS1QM1pwLVljbEVXSDNxaGtrOTh3UVNYYmZSc1BKWllranl4WGNtbElPem50VUE?oc=5", "source_name": "TradingView", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQdE1YXzZsMmVlLWFkTWZZLVNyTm1DNGtGYzZGODZCSk84aDUwd0xoTDNmZDdTM1FXVjlpWFVjb09RcEpoaWhVSDEwZmFqSHR0WHdWc3Q4STk5bzhPLS1NWWZtNnJzU2tEa1FYVGRldndJNVA4WVZ4OWR1Mm0wVjdmeGx0dlh3Q3ppdm9nSVdsZzRfYVZHWFJSMFVMSkY?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd (NASDAQ:IVVD) Q1 Miss Sends Shares Lower as PEMGARDA Revenue Falls Short and R&D Costs Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQYnhBTkdFZW11cFRZbTBZOGI1ZmttTjRtNVpyZTN2VXJERFEyOHlnelRGOVB5NlgwSFhNeXBmSHg3ZERUSVE2a0FqdWQ2Zng4RHM2d2ZEYXRVajMzMHdLNkc3aHJtbE02LWJXX0s1RFNWZDV3ODB6Y2FQRnlnSjk4cGJtMTNnNFZLSGNwRHlqU2M1VkJCMVAzM2Q4cVE3dEZhZEpKZDRldnhrZEVQZ0ZQdHFrZGxOVms3WUNDdUVQcUM4ZlMxbVppMllTWUl1X3pmU0hEcm0yejk3MUoxaC1yWmp3?oc=5", "source_name": "ChartMill", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Invivyd sets May 14 webcast for quarterly results and business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPMnZEU0owZWJlVkV5c21EdkFXcm1kVGRubHRiZFBQdGRKRTBBVTIxQnBTc0RWNjQ2QS1PSEdrVnE5ZmVxejMzS011RUJDZzJYX2dkRWxva3lGVzVzQ1lHMHVBUm9NWkR0eDJBREdxeVB5U3Rvc1hYMDY0eDMzSnVsYVlvUnJ0dGg0U1hlY29FeHJaWXdGSlNTR2c2cFdHbFNNS0I0aHUtNzBGUUw1aFRUemdzT2ZPYjBNYkRhWVRn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNcm1la3gwcWkyOWhfUFFFa2xLTUVSNHNLaGhqa1dlZGlRcW1SSU1RNlVrWUJjUy1XUVAzMm9tR3ZleWw0Y0dJOEVSRURxQVJJZG41N09fLU9jbnF5a2NnQzZXVGtiUE5NNE1RQi1NUEUyWFdSLWxlM0owdnhhUGJ6aW9rUUdKX2NtdmtLeFQyQkhEM1I1UWZVWm0yNGJHX1lDNWdoNmw0UFVlLWoxUlZ1X2U5NG9hN3Z0dmRIZWpvZGhlLUdaT2VYcDFJZElCaEdHdVVMbF8ySVPSAd4BQVVfeXFMTUtRRmk4NGRRLUxqYlR3NWZSSXVtSmRCdnlzR01nVEhRLVJqbzkyUGdyeG5jY3hOYVYzUU5lTU5NcFA1SjYwRHpXVm5JYWZTVFppR2d0TDNmN05xTWctU1lfSUpJWDJ2VTgxTXd3aWY0azlqUUdWVUt0Y1VLTVZXbHFoVmRMbnRKMmQzdmZzaG81ZjlFMTZnRjVuUFhrTERTUS0ycTh2dVk2cHJGU1FNelZud1hReVV2LUJiV1cwVEpzb25fc0RhSzMzdVZLS29JcG9jYXBCYUYxVW1Rb3Jn?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors in Invivyd, Inc. (NASDAQ:IVVD) see US$113m decrease in market cap last week, although long-term gains have benefitted them.", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNS2JzWVhXOTNDZ0NzSFdCQlAwamFYRElTQjlVMnZMMzdwSEEtR0FjT3NkNHdNSFVLOUxKVGVhUFFMdWFVSXYxaTdOM2FKUW9DT1pfcGoxY0ZfMkpsT2xrM2pMOTh6R24weVRkVUk5V05haFVFdmRoTUx4MjZ6cXc1bWJYdHgyRnJlMVE?oc=5", "source_name": "Market source", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQaG1yVXh6QmwxSUJBT1dhczBvNkVEM2c2eXVUWnpoNmhSQUU5LW4xTzBCRzVvanJLdWlWU2xseUdFRU9pcVpvRUM5Zy1oVUFnbEdaZHB2YlhKRGJWLUxuakZzc21aNEM0a2RMWmJiUEFNVmxRd1dibzVtci1Tb0RLRQ?oc=5", "source_name": "Market source", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kevin McLaughlin Buys Handful Of Shares In Invivyd", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Here's Why We're Not Too Worried About Invivyd's (NASDAQ:IVVD) Cash Burn Situation", "summary": "Invivyd (NASDAQ:IVVD) has a cash runway of about 2.3 years and analysts predict the company will reach cashflow breakeven in 3 years. While its cash burn of US$79m represents 32% of its market capitalization, which could lead to dilution if more capital is needed, its 52% revenue", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ivvd/invivyd/news/heres-why-were-not-too-worried-about-invivyds-nasdaqivvd-cas", "source_name": "Simply Wall Street", "published_at": "2026-07-10T18:11:22", "published_display": "10 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK)", "summary": "Analysts have provided varied ratings for three healthcare companies. Stifel Nicolaus maintained a Buy rating for Cipher Pharmaceuticals with a C$22.00 price target, while Cantor Fitzgerald maintained a Buy rating for Invivyd with a $10.00 price target. Morgan Stanley, however, i", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/3223856/analysts-conflicted-on-these-healthcare-names-cipher-pharmaceuticals-othercphrf-invivyd-ivvd-and-merck-company-mrk/", "source_name": "The Globe and Mail", "published_at": "2026-07-10T13:10:02", "published_display": "10 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Inc updates investors on its antiviral pipeline as Nasdaq-listed biotech advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQenBFbDV6Ymt1S1BCTWN0Wk5CanRrOHdXQVFKTFdFeWdYai0tN3NGSmltWkcyS2JXUGtjVTFXNzBoOVlXd2FxYmtiRU5DQ0Y1UzdwZ1piQ2VHY1NnOVpTcENvQ2ZiNThVR3NmcHI4SzNERjN2SVBuQ3R1Y2E2UV93bVJ1OE80UlZCWE5RaUlPRldmeHdTZXVpSHE3TVFHc3Jiel9HeEJhREZYdnAzQlhfZ3J0bm04Y29ielRzaGlxUFpsaUJ2R0lhNnp2aw?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-08T19:48:57+00:00", "published_display": "08 Jul 2026 19:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Invivyd stock rating on regulatory path", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Invivyd Inc. (NASDAQ:IVVD) following recent regulatory developments regarding its COVID-19 antibody treatment, PEMGARDA. The FDA issued a Notice of Termination for PEMGARDA's Emergency Use Authorization, ef", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-invivyd-stock-rating-on-regulatory-path-93CH-4781353", "source_name": "Investing.com", "published_at": "2026-07-08T17:09:06", "published_display": "08 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Invivyd stock rating on regulatory path By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Invivyd Inc. (NASDAQ:IVVD) following recent regulatory developments regarding its COVID-19 antibody treatment, PEMGARDA. The FDA issued a Notice of Termination for PEMGARDA's Emergency Use Authorization, ef", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-reiterates-invivyd-stock-rating-on-regulatory-path-93CH-2590809", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T11:40:48", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-Down", "summary": "Invivyd, Inc. announced that the FDA issued a notice of termination for the Emergency Use Authorization (EUA) of PEMGARDA (pemivibart) due to the wind-down of the COVID-19 Public Health Emergency Declaration by the U.S. Department of Health and Human Services. The termination bec", "url": "https://www.moomoo.com/news/post/72540865/invivyd-inc-announces-fda-notice-of-termination-for-pemgarda-eua", "source_name": "Moomoo", "published_at": "2026-07-08T06:43:41", "published_display": "08 Jul 2026 06:43", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Inc stock and Covid antibody focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTzAxb01JbGh3UzZXZHl6N2lGWUdSOXpGVTdZOTdWbGYzUzRDTkJQeDlJUXprbzdIVXNGVEpYYUlIRE8xb015UVBISUhteHdOakRWZ09ja3RBeEdfazBLdnFMRzltUlE0X1VJekFqSFpiaDFQNDYzbXgzWWdkR1hwVlhySnh5c1psMUhzOWJDRkd4Yk1vWkt1S0pBc3VORktlMW1Z?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-07T14:22:39+00:00", "published_display": "07 Jul 2026 14:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 \u2014 Invivyd Eyes Full FDA Approval", "summary": "", "url": "https://finance.yahoo.com/m/deafdf7c-ee7e-3b54-bb3d-bb9ab2b2d2f7/ivvd-stock-drops-as-pemgarda.html", "source_name": "Stocktwits", "published_at": "2026-07-06T17:39:27+00:00", "published_display": "06 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd receives 12-month notice of EUA termination for PEMGARDA, plans FDA dialogue", "summary": "Invivyd has received a 12-month notice from the FDA regarding the termination of the Emergency Use Authorization (EUA) for its drug PEMGARDA, effective June 29, 2027, following a similar declaration from HHS concerning COVID-19 EUAs. The company is actively discussing with the FD", "url": "https://www.tradingview.com/news/tradingview:4c29114ade7cb:0-invivyd-receives-12-month-notice-of-eua-termination-for-pemgarda-plans-fda-dialogue/", "source_name": "TradingView", "published_at": "2026-07-06T16:40:48", "published_display": "06 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVVD Stock Tanks 19% Today \u2013 But This Analyst Believes It Has A Potential Upside Of Over 730%", "summary": "Invivyd Inc. (IVVD) stock dropped over 19% after reporting first-quarter revenue of $13.7 million, significantly missing analyst estimates of $18 million. Despite this, H.C. Wainwright & Co. reiterated a 'Buy' rating and a $10 price target, suggesting a potential upside of over 7", "url": "https://stocktwits.com/news-articles/markets/equity/ivvd-stock-fell-today-but-this-analyst-sees-730-percent-upside/cZX1UFNReSa", "source_name": "Stocktwits", "published_at": "2026-07-06T16:14:45", "published_display": "06 Jul 2026 16:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Gets FDA Notice of Pemgarda COVID-19 Emergency Use Authorization Termination", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/invivyd-gets-fda-notice-pemgarda-114042026.html", "source_name": "MT Newswires", "published_at": "2026-07-06T11:40:42+00:00", "published_display": "06 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd receives FDA termination notice for PEMGARDA EUA", "summary": "Invivyd (NASDAQ:IVVD) announced that the FDA's Emergency Use Authorization for its COVID-19 antibody treatment, PEMGARDA, will terminate on June 29, 2027. This decision aligns with the Department of Health and Human Services' conclusion of the national COVID-19 emergency declarat", "url": "https://grafa.com/en/news/united-states/invivyd-ivvd-pemgarda-eua-termination-notice-2027", "source_name": "grafa.com", "published_at": "2026-07-06T12:21:00", "published_display": "06 Jul 2026 12:21", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Announces Receipt of Twelve Months\u2019 Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA\u00ae and Provides an Update on Next Steps with the U.S. FDA", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/invivyd-announces-receipt-twelve-months-110100684.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T11:01:00+00:00", "published_display": "06 Jul 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd (NASDAQ: IVVD) faces 2027 end of PEMGARDA COVID EUA", "summary": "Invivyd (NASDAQ: IVVD) announced that the FDA has issued a Notice of Termination for the Emergency Use Authorization (EUA) of its COVID-19 monoclonal antibody, PEMGARDA, effective June 29, 2027. This follows the HHS's decision to end the COVID-19 EUA declaration. PEMGARDA will re", "url": "https://www.stocktitan.net/sec-filings/IVVD/8-k-invivyd-inc-reports-material-event-d43329ab1d20.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:11:44", "published_display": "06 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEMGARDA faces 2027 EUA end as Invivyd talks next steps with FDA", "summary": "Invivyd (Nasdaq: IVVD) has received advanced notice from the FDA that the Emergency Use Authorization (EUA) for its COVID-19 preventative treatment, PEMGARDA, will terminate on June 29, 2027, following the planned end of the HHS COVID-19 EUA declaration. Despite this, Invivyd is ", "url": "https://www.stocktitan.net/news/IVVD/invivyd-announces-receipt-of-twelve-months-advanced-notice-of-jcshku0pngsg.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:11:43", "published_display": "06 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVVD - Invivyd Inc Short Interest", "summary": "This article provides a detailed financial overview and short interest data for Invivyd Inc (IVVD). It includes key metrics such as market capitalization, sales, earnings per share, and various performance indicators. The data highlights the company's short interest, institutiona", "url": "https://finviz.com/stock?t=IVVD&p=w&r=y2&ty=si", "source_name": "Finviz", "published_at": "2026-07-05T19:40:40", "published_display": "05 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Invivyd, Inc. \u2013 NASDAQ:IVVD", "summary": "This article provides the \"Price to sales forward\" metric for Invivyd, Inc. (NASDAQ: IVVD). It appears to be a financial data snippet from TradingView, focusing on a single financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-IVVD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T16:11:44", "published_display": "05 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Invivyd, Inc. \u2013 NASDAQ:IVVD", "summary": "This article provides financial information for Invivyd, Inc. (NASDAQ: IVVD), specifically focusing on its forward price-to-earnings ratio. It directs users to TradingView for market data, technical analysis, and other financial tools related to the company. The content appears t", "url": "https://www.tradingview.com/symbols/NASDAQ-IVVD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:39:42", "published_display": "05 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IVVD - Invivyd Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Invivyd Inc. (IVVD), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider/institutional ownership, short interes", "url": "https://finviz.com/stock?t=IVVD&ta=1&p=d&ty=fc", "source_name": "Finviz", "published_at": "2026-07-04T12:09:47", "published_display": "04 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Invivyd, Inc. \u2013 NASDAQ:IVVD", "summary": "This article briefly presents the \"Enterprise value to EBITDA forward\" metric for Invivyd, Inc. (NASDAQ:IVVD) within the TradingView platform. It shows the company's stock market information and indicates that the market is closed with no trades. The article is a stub, likely par", "url": "https://www.tradingview.com/symbols/NASDAQ-IVVD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:10:44", "published_display": "04 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Invivyd, Inc. announced that it granted 14 newly hired non-executive employees options to purchase 493,000 shares of its common stock as an inducement to employment. These options were issued on July 1, 2026, under Nasdaq Listing Rule 5635(c)(4) and the company's 2026 Inducement ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IVVD/pressreleases/3095627/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/", "source_name": "The Globe and Mail", "published_at": "2026-07-03T03:10:44", "published_display": "03 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd gives 14 new hires stock options worth 493,000 shares", "summary": "Invivyd (Nasdaq: IVVD) announced it granted 493,000 stock options to 14 newly hired non-executive employees as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.8544 per share, matching the closing price on t", "url": "https://www.stocktitan.net/news/IVVD/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-oyczlwl9qiln.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:12:30", "published_display": "02 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Value Benchmark Index", "summary": "Invivyd, Inc. (NasdaqGM: IVVD) has been added to the Russell Microcap Value Benchmark Index. This news follows a series of recent index inclusions for the biopharmaceutical company, which also saw its addition to the Russell 2000 Index and Russell 2000 Value Benchmark Index on th", "url": "https://www.marketscreener.com/news/invivyd-inc-nasdaqgm-ivvd-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8bff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:15:24", "published_display": "29 Jun 2026 16:15", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Index", "summary": "Invivyd, Inc. (NasdaqGM: IVVD) has been added to the Russell Microcap Index. This follows a recent period of news for the biopharmaceutical company, including its completion of enrollment in a Phase 3 clinical trial for a COVID-19 antibody. The company specializes in developing a", "url": "https://www.marketscreener.com/news/invivyd-inc-nasdaqgm-ivvd-added-to-russell-microcap-index-ce7f5fdedd88f721", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:09:55", "published_display": "29 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc. Actuals & Estimates (NASDAQ:IVVD)", "summary": "This article provides an overview of Invivyd, Inc. (NASDAQ: IVVD) stock, including its current price, historical performance, analyst forecasts, and key financial metrics. It details earnings, revenue, market capitalization, and volatility, and confirms that the company does not ", "url": "https://www.tradingview.com/symbols/NASDAQ-IVVD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:37", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Shareholder Notice", "summary": "Faruqi & Faruqi, LLP is investigating potential securities claims against Invivyd, Inc. (NASDAQ: IVVD) and encouraging investors who lost over $100,000 to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Invivyd made misleading statements ", "url": "https://www.newsfilecorp.com/release/157908/Invivyd-Shareholder-Notice?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-25T02:10:07", "published_display": "25 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lobbying Update: $60,000 of INVIVYD INC. lobbying was just disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbnRjSXdPYmZiaURVam16VHhkQ0ZuNGNPQUtUalFvc3ZZZkd3MktFY1lCY1R6U1lBbWs4dF9mLTN0WVBEaE9tLXZUOEo4WlhBZnh1QVpqLTVndTFLY0NoN3drMUw5Vm4za01yd0xFR2c3akNPRzJDaWJHV1M2ZXFKVVBPZml0cmlIaURyNTNnYzNXWVlLNHByWjY1aHpKSWpFWXRUcG1hazJOZDA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Inc (IVVD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Invivyd Inc (IVVD) has a robust financial status with a current financial score of 8.37, ranking 63 out of 157 in the Pharmaceuticals industry. The company reported a significant year-over-year revenue increase of 21.59% to 13.74M and a net profit increase of 154.16%. Its strong ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ivvd/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T08:10:05", "published_display": "23 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Biotechnology Select Industry Index", "summary": "Invivyd, Inc. (NasdaqGM: IVVD) has been removed from the S&P Biotechnology Select Industry Index. This news follows several recent updates from the company, including the completion of enrollment in its Phase 3 LIBERTY clinical trial for its VYD2311 antibody against COVID-19. Inv", "url": "https://www.marketscreener.com/news/invivyd-inc-nasdaqgm-ivvd-dropped-from-s-p-biotechnology-select-industry-index-ce7f5cd3d88af222", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:40:21", "published_display": "22 Jun 2026 01:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311", "summary": "Invivyd Inc. (NASDAQ: IVVD) has dosed the first participants in its LIBERTY Phase 3 clinical trial for VYD2311, a monoclonal antibody candidate for COVID-19 prevention. This study will compare VYD2311's safety and tolerability against mRNA COVID-19 vaccines in approximately 210 h", "url": "https://www.insidermonkey.com/blog/invivyd-ivvd-doses-first-participants-in-phase-3-trial-for-vyd2311-1783916/", "source_name": "Insider Monkey", "published_at": "2026-06-19T07:14:42", "published_display": "19 Jun 2026 07:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Invivyd Inc (IVVD) has an earnings forecast score of 8.67, ranking 13th in the Pharmaceuticals industry. Analysts have set an average price target of $10.00 for IVVD, with most recommending a \"Buy\" trend. The company's expected revenue for the next quarter is $14.40 million, and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ivvd/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:03", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 79, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/invivyd-apos-stage-trial-covid-113133374.html", "source_name": "MT Newswires", "published_at": "2026-06-16T11:31:33+00:00", "published_display": "16 Jun 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/invivyd-announces-completion-enrollment-phase-110100561.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:01:00+00:00", "published_display": "16 Jun 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd doses first participants in Phase 3 COVID-19 trial", "summary": "", "url": "https://finance.yahoo.com/m/b248705d-ddec-3f8d-b220-660c9bc473f6/invivyd-doses-first.html", "source_name": "Proactive", "published_at": "2026-06-09T16:22:00+00:00", "published_display": "09 Jun 2026 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Doses First Participants in Phase 3 Trial of COVID-19 Antibody VYD2311", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/invivyd-doses-first-participants-phase-121506548.html", "source_name": "MT Newswires", "published_at": "2026-06-09T12:15:06+00:00", "published_display": "09 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New COVID shot alternative faces off with mRNA vaccine in Invivyd trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWEpNakhUaUdha1lVNktOTnNqaDd5cG5HYld6ZThzaGpFVXBpQmROb0FycGstOFduSDlpeWk1WlRPSmJwei1naXh6N2RhNUllQWt5YzZtVml5ckpEM1JaTUJsRV9KSEtJQUNqOTF1d0pTUFVtMGVkTDZsYTBEUDYtTUtsM0dzamJNYWpWdzFPUHZ6UEpZNkZRNW1GanF0X2RZNVgxWFZ4c1pCNkZfcl9pelI3dklLX1V5a0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd offers stock options to 17 new hires at $1.22 each", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMEEzZm5FV1Y4cExMRm1Xa2VablFZMW9wSGdRS2ZhOWpLbThnNm9HTWprUElYTEtZOUs1N1owTXliSGQzbVRYa3MzODlNc1lta2c0d0t4NVRQbDRFRFBnOXZXN3VPOExQdnh2dVl1WWtYZnBNRnpqVzRkSG13RWs4NVJTME9YTXpYR2o0MWdJemYzVGNBSnY0NUVKRWFEUzVzd2ljUlE3TzFWekp3VmdLWTZ0dzd4b19ZMGhsSnBR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COVID antibody trial fully enrolled as Invivyd targets Q3 2026 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPRnlXX3BYbTl6NHkzNmRSbXVWeHBPbHpXYkU4d2xYaXZOazNHVzI3WkhhOUxnTDRHNDNYVHVwZkh1cFBma3lyUGlRaEtWUUdRQ2lPQWoyb3gxVmR6OENjS1YwZ0pReXQ0UkVRckg4aHRxU0h5N1NxQktUbEpvWm5yXzY3LW1kQmhScjlIWW9pc3lzWkp4T3hQSzRQeksyQ2dtSmF5VnZjQk5jTWJ0LWVEdG4xRU9ERFNRS0pRSA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd lines up three June investor events with live webcasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNM0tISERzN1Q2M0JXRU4xMTA2d3Z0ZWFTc0lkRlQ3YkpNSHQteHRfQ1FXQ1hqYzYwanFidjZleTY2d3Q0LUVybXM3SXU4Y0ItNEVmanQxLWhrN0hmTW1VUUdncmwxWnRXTEZoek5ILTQwNFBfNS1kcUxRQXg5dzR1VVVWVE1lMzNmSERueUNQQTh0cW8xUkpLcmFHZTYtbXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNX0R5UDVoWmFwZEtYZWV1WGJmb0lOY3pxSWF0eUluc0hUbU4zNHNUMzR1TTNBWWZMVnhuV1ZIcWRick5lU0ZMeGIxN2VhbGlPTWt0d1R1RGtac2tEN3h3ZVY2QU0wc0ZFaWFJUDE0ZHJrZVdRTWJBM3ItRUxwUE9hT3c1ZWhKdGRvRGNZRTRGYmZMaHgtSnlJ?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOVDJOdTFuQzN6T1I2amZJdTNCNV9ZUEFnWDdZWmhOZWxUaTg1YWdMSjRldTNKUXJzQ1ctZFBJYjcyWkRMelcwM3NkbE9hSzZNNExKZ3RjaFZGa09PRnZDN3VkTGR1MTN4Wl9VOENYRzhCNVJFTHVQaDNFbDd4U2Y2dnRfYm5lbzRxS2d6ajdQd2xQSk0teW5pQS1QM1pwLVljbEVXSDNxaGtrOTh3UVNYYmZSc1BKWllranl4WGNtbElPem50VUE?oc=5", "source_name": "TradingView", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQdE1YXzZsMmVlLWFkTWZZLVNyTm1DNGtGYzZGODZCSk84aDUwd0xoTDNmZDdTM1FXVjlpWFVjb09RcEpoaWhVSDEwZmFqSHR0WHdWc3Q4STk5bzhPLS1NWWZtNnJzU2tEa1FYVGRldndJNVA4WVZ4OWR1Mm0wVjdmeGx0dlh3Q3ppdm9nSVdsZzRfYVZHWFJSMFVMSkY?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd (NASDAQ:IVVD) Q1 Miss Sends Shares Lower as PEMGARDA Revenue Falls Short and R&D Costs Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQYnhBTkdFZW11cFRZbTBZOGI1ZmttTjRtNVpyZTN2VXJERFEyOHlnelRGOVB5NlgwSFhNeXBmSHg3ZERUSVE2a0FqdWQ2Zng4RHM2d2ZEYXRVajMzMHdLNkc3aHJtbE02LWJXX0s1RFNWZDV3ODB6Y2FQRnlnSjk4cGJtMTNnNFZLSGNwRHlqU2M1VkJCMVAzM2Q4cVE3dEZhZEpKZDRldnhrZEVQZ0ZQdHFrZGxOVms3WUNDdUVQcUM4ZlMxbVppMllTWUl1X3pmU0hEcm0yejk3MUoxaC1yWmp3?oc=5", "source_name": "ChartMill", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd sets May 14 webcast for quarterly results and business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPMnZEU0owZWJlVkV5c21EdkFXcm1kVGRubHRiZFBQdGRKRTBBVTIxQnBTc0RWNjQ2QS1PSEdrVnE5ZmVxejMzS011RUJDZzJYX2dkRWxva3lGVzVzQ1lHMHVBUm9NWkR0eDJBREdxeVB5U3Rvc1hYMDY0eDMzSnVsYVlvUnJ0dGg0U1hlY29FeHJaWXdGSlNTR2c2cFdHbFNNS0I0aHUtNzBGUUw1aFRUemdzT2ZPYjBNYkRhWVRn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors in Invivyd, Inc. (NASDAQ:IVVD) see US$113m decrease in market cap last week, although long-term gains have benefitted them.", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNS2JzWVhXOTNDZ0NzSFdCQlAwamFYRElTQjlVMnZMMzdwSEEtR0FjT3NkNHdNSFVLOUxKVGVhUFFMdWFVSXYxaTdOM2FKUW9DT1pfcGoxY0ZfMkpsT2xrM2pMOTh6R24weVRkVUk5V05haFVFdmRoTUx4MjZ6cXc1bWJYdHgyRnJlMVE?oc=5", "source_name": "Market source", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQaG1yVXh6QmwxSUJBT1dhczBvNkVEM2c2eXVUWnpoNmhSQUU5LW4xTzBCRzVvanJLdWlWU2xseUdFRU9pcVpvRUM5Zy1oVUFnbEdaZHB2YlhKRGJWLUxuakZzc21aNEM0a2RMWmJiUEFNVmxRd1dibzVtci1Tb0RLRQ?oc=5", "source_name": "Market source", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kevin McLaughlin Buys Handful Of Shares In Invivyd", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 58, "sentiment_summary": {"positive": 12, "negative": 12, "neutral": 34, "score": 50, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 9.21, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 0.78, "latest_week": "2026-07-10", "one_week_move": -12.4, "four_week_move": 1.7, "twelve_week_move": -55.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.719291, "market_dynamics_buy_signal": false, "relative_strength": -56.155589, "fair_value_gap": -51.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.1297, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-12.4% over one week, +1.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "MT Newswires", "count": 3}, {"label": "www.marketscreener.com", "count": 3}, {"label": "The Globe and Mail", "count": 2}, {"label": "ad-hoc-news.de", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-12.4% over one week, +1.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Here's Why We're Not Too Worried About Invivyd's (NASDAQ:IVVD) Cash Burn Situation"}], "updated_at": "2026-07-18T03:12:51.076933+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}